Comparison of beta-endorphin and CGRP levels before and after treatment for severe schizophrenia

Figures & data

Table 1 PANSS and PANSS subscale rates (points) in patients subtype with positive symptoms and in patients subtype with negative symptoms (Mann–Whitney U test)

Variable	Rank sum		Z	P-value
	Positive subtype patients	Negative subtype patients
PANSS	1,959,000	456,000	2.37094	0.0177
PANSS G	1,708,000	707,000	−1.04540	0.2958
PANSS P	2,244,000	171,000	6.26556	0.0000
PANSS N	1,364,000	1,051,000	−5.74627	0.0000
Composite index	2,244,000	171,000	6.26556	0.0000

Abbreviation: PANSS, Positive and Negative Syndrome Scale.

Figure 1 Comparison of beta-endorphin concentrations in patients with positive symptoms (PP), and patients with negative symptoms (PN) before treatment (β-end1) and in stable mental state after treatment (β-end2) with controls (C, β-end-C) and first-degree relatives (R, β-end-R).

Figure 2 Comparison of CGRP concentrations in patients with positive symptoms (PP), and patients with negative symptoms (PN) before treatment (CGRP1) and in stable mental state after treatment (CGRP2) with controls (C, CGRP-C) and first-degree relatives (R, CGRP-R).

Abbreviation: CGRP, calcitonin gene-related peptide.